Have you read this JDD consensus on advanced topical nonsteroidal therapies for atopic dermatitis?
A recent retrospective analysis using the TriNetX research network compared patients with non scarring hair loss who received minoxidil with matched controls. The authors of this JDD article report statistically significant associations between minoxidil exposure and diagnoses related to rosacea, including rosacea conjunctivitis and other rosacea subtypes. The investigators note a physiologic rationale because minoxidil is a vasodilator and hypothesize that vasodilation could alter cutaneous vascular homeostasis in erythematotelangiectatic rosacea.
This study used real world electronic medical record data and propensity score matching to address confounding. It is observational and relies on diagnostic coding, so the findings describe associations and do not establish causality. The authors acknowledge limitations including potential misclassification, residual confounding, and the inability to determine timing or adherence from records alone.
For practicing dermatology clinicians and dermatologists this report may prompt awareness when prescribing topical or low dose oral minoxidil to patients with a history of facial erythema or rosacea. It also suggests a signal worth examining in prospective studies and targeted pharmacovigilance.
Read the full JDD article for detailed methods, subgroup analyses, and tables, and consider whether reviewing recent patient cases or discussing these findings with colleagues is warranted in your practice.
J Drugs Dermatol. 2026;25(3). doi:10.36849/JDD.9767
Blog write-up assisted by AI
